Gleevec vs Sprycel

[Guest guest]

Researchers affiliated with the START-C (CA180-013) international multi-center

study reported updated outcomes of 387 patients with chronic-phase CML and

resistance or intolerance to imatinib who where treated with dasatinib.3 Median

time from diagnosis to treatment with dasatinib was 61 months; 65% had also

received interferon, 10% had received a stem cell transplant, and 55% had

received 600 mg/day or more of imatinib. The minimal follow-up time for this

group of patients is now 24 months. The major findings were:

a.. Complete hematologic remission in 91%

b.. Major cytogenetic response in 62%

c.. Complete cytogenetic response rin 53%

d.. Major molecular response in 47%

e.. Major cytogenetic response in 55% of imatinib-resistant patients

f.. Major cytogenetic responses in 63% of patients with BCR-ABL mutations

g.. Complete cytogenetic response rate of 78% for imatinib-intolerant patients

h.. Major molecular response rate of 78% for imatinib-tolerant patients

i.. Major cytogenetic response maintained for at least 24 months in 88%

j.. Two-year progression-free survival of 80%

k.. Two-year overall survival of 94% (100% for imatinib-intolerant patients)

Dose interruptions were required for the majority of patients. There were few

new toxicities occurring between 12 and 24 months of treatment. The authors

conclude that dasatinib was well tolerated and that cytogenetic responses were

durable.

http://www.caring4cancer.com/go/leukemia/news?NewsItemId=43143

Blessings,

Lottie